Health Care [ 8/12 ] | Biotechnology [ 34/74 ]
NASDAQ | Common Stock
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia.
The company was incorporated in 1990 and is headquartered in Foster City, California.
Reported date | EPSChange YoY | EstimateSurprise |
---|---|---|
Feb 26, 25 | -0.04 Increased by +60.44% | -0.05 Increased by +23.28% |
Nov 7, 24 | -0.04 Increased by +50.00% | -0.08 Increased by +50.00% |
Aug 8, 24 | -0.10 Decreased by -11.11% | -0.10 |
May 2, 24 | -0.09 Decreased by -28.57% | -0.10 Increased by +10.00% |
Feb 28, 24 | -0.09 Increased by +10.00% | -0.10 Increased by +10.00% |
Nov 2, 23 | -0.08 Increased by +20.00% | -0.10 Increased by +20.00% |
Aug 3, 23 | -0.09 Decreased by -28.57% | -0.08 Decreased by -12.50% |
May 11, 23 | -0.07 Increased by +22.22% | -0.10 Increased by +30.00% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Dec 31, 24 | 47.54 M Increased by +206.58 K% | -25.35 M Increased by +51.22% | Decreased by -53.33% Increased by +99.98% |
Sep 30, 24 | 28.27 M Increased by +17.14 K% | -26.45 M Increased by +40.97% | Decreased by -93.55% Increased by +99.66% |
Jun 30, 24 | 882.00 K Increased by +2.94 K% | -67.38 M Decreased by -36.88% | Decreased by -7.64 K% Increased by +95.50% |
Mar 31, 24 | 304.00 K Increased by +1.35 K% | -55.39 M Decreased by -45.48% | Decreased by -18.22 K% Increased by +89.95% |
Dec 31, 23 | 23.00 K Decreased by -77.67% | -51.97 M Decreased by -22.56% | Decreased by -225.97 K% Decreased by -448.87% |
Sep 30, 23 | 164.00 K Decreased by -44.78% | -44.80 M Decreased by -9.75% | Decreased by -27.32 K% Decreased by -98.75% |
Jun 30, 23 | 29.00 K Decreased by -60.27% | -49.23 M Decreased by -74.21% | Decreased by -169.75 K% Decreased by -338.52% |
Mar 31, 23 | 21.00 K Decreased by -82.93% | -38.07 M Decreased by -20.79% | Decreased by -181.30 K% Decreased by -607.48% |